Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CD38 expression levels and lymphocyte subsets, including CD38-positive Treg cells, before and after Daratumumab treatment in relapsed/refractory Multiple Myeloma Patients

Trial Profile

CD38 expression levels and lymphocyte subsets, including CD38-positive Treg cells, before and after Daratumumab treatment in relapsed/refractory Multiple Myeloma Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs Daratumumab (Primary)
  • Indications Multiple myeloma
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 26 Jul 2018 New trial record
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top